-
Potential Threat of Newly Identified ST20 Clone to Enzyme Inhibitor Combination Therapy: Findings from ESCMID Global 2024
Carbapenem-resistant Klebsiella pneumoniae (CRKP) has emerged as a significant challenge in nosocomial infections, with its resistance escalating, drawing global attention. At the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), a study by Professor Yunsong Yu’s team from the Affiliated Hospital of Zhejiang University School of Medicine presented the latest findings…
-
Professor Guosheng Ren: Highlighting the French-Chinese Breast Cancer Forum, New Technologies Lead Developments in Breast-Conserving Surgery | 2024 SFBCS
In the vibrant spring of April in Chongqing, from April 19 to April 20, 2024, the “11th Sino-French (International) Advanced Breast Cancer Forum (SFBCS)” was held, co-hosted by several prestigious institutions including the Chinese Anti-Cancer Association’s Breast Cancer Committee, the Breast Surgery Expert Group of the Chinese Medical Doctor Association, the Oncology Clinical Research Management…
-
Professor Yongsheng Wang: Precision Decision-Making in Sentinel Lymph Node Biopsy—Selecting the Right Patient Population, Diagnosis, and Clinical Management | 2024 SFBCS
The 11th Sino-French (International) Advanced Breast Cancer Forum (SFBCS) was held in Chongqing on April 19-20, 2024. Experts from around the world shared their knowledge on basic breast cancer research, pathology diagnosis, surgical procedures, and systemic treatment. In the surgical forefront segment, Professor Yongsheng Wang from Shandong Cancer Hospital presented on “Precision Decision-Making in Sentinel…
-
Professor Jun Ma : Continuous Innovation in Drugs Powers the Transition of Cancer into Chronic Disease Management
For cancer patients, prolonged drug therapy, particularly intravenous treatments, can lead to various inconveniences like infusion reactions and phlebitis. The emergence of new formulations of anticancer drugs not only reduces treatment costs and saves time but also brings convenience to both patients and clinicians. In an era where chronic disease management is becoming more prevalent,…
-
EBMT China Voice | Dr. Yishan Ye : Comparative Study of Haploidentical, Sibling Matched, and Unrelated Matched Allogeneic Hematopoietic Stem Cell Transplantation in Core Binding Factor AML Patients in Second Complete Remission (CR2)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a crucial therapeutic option for a variety of benign and malignant hematological diseases. In recent years, the proportion of haploidentical transplants has been increasing due to advancements in the technology. From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting…
-
Professor Xinan Sheng’s Insights on Key Studies in Kidney Cancer at the 2024 ASCO-GU Annual Meeting | ASCO-GU Highlights Reviewed by Key Opinion Leaders
The 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) was held from January 25th to 27th in San Francisco, showcasing the most innovative scientific advancements in the field and discussing future treatment directions for genitourinary cancers. Among them, several groundbreaking studies in the field of kidney cancer were presented, and “Oncology Frontier” invited…
-
Professor Ning Shen’s Team: Mechanism of Resistance to Cefiderocol in Highly Virulent Klebsiella pneumoniae | ESCMID Global 2024
As the global issue of antimicrobial resistance intensifies, newly emerging resistant bacterial strains pose a significant threat to public health. At the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), a study by Professor Ning Shen’s team from Peking University Third Hospital (Abstract No.: E0451) focused on the resistance issues of…
-
ASCO GU Researcher Speaks丨Professor St-Laurent: Urinary Tumor DNA Detects Minimal Residual Disease, Aiding in Extended Patient Survival
The ASCO-GU 2024, a major event in the field of urologic oncology, was held in San Francisco, USA, showcasing numerous innovative research advancements and discussing future treatment directions for urologic and male reproductive system tumors. For patients with non-muscle invasive bladder cancer (NMIBC) who do not respond to Bacillus Calmette-Guérin (BCG) treatment, there remains a…
Connecting Medical Expertise through Media